Boston-based Alexion’s Ultomiris (ravulizumab-cwvz) hit the primary objective in a Phase III study of complement inhibitor-naïve patients with atypical hemolytic uremic syndrome.
Researchers with Cortexyme published research in the journal Science Advances describing the role of Porphyromonas gingivalis, a bacteria that causes gingivitis, to Alzheimer’s disease.
Clinical Trial Finds Formula in Merix Pharmaceutical’s RELEEV 1 Day Cold Sore Highly Active Against Herpes
Merix Pharmaceutical Corp. announced the company’s proprietary botanical extract formula VIRACEA was found to be highly active against HSV-1 and HSV-2 in laboratory testing.
A new report released by researchers at Yale University could change the way some HIV patients are treated.
Scientists at DZNE, HIH, and the University Hospital Tuebingen identified a protein in blood that can precisely track Alzheimer’s disease progression before the first symptoms appear.
China government officials told the Xinhua News Agency that the researcher who became world famous for using CRISPR on human embryos “will be transferred to public security authorities,” and the individuals involved in the research will be “severely dealt with according to the law.”
The miniature robot – the bacteria-inspired brainchild of a team of scientists in Switzerland seeking new methods to deliver drugs to diseased tissue – is designed to wend its way through blood vessels and other systems in the body.
AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
Janssen Pharmaceutical and Apple have teamed up to determine if a new app for the Apple Watch – which has a built-in electrocardiogram – can improve the health of more than 30 million people with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications.
JLL’s life sciences experts anticipate that Big Pharma during 2019 will adopt agile real estate strategies and more entrepreneurial approaches to reinvent R&D and compete with smaller enterprises that are doubling down on product innovation and delivery.